Study of Immunity Dysfunction Induced by Extracorporeal Assistance (ECMO / ECLS)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03262155

Acronym

IMPEC

Enrollment

Registered

2017-08-25

Start date

2017-01-01

Completion date

2019-01-31

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome, Cardiogenic Shock

Brief summary

Study of immunosuppression biomarkers in patients with ARDS or cardiogenic shock with ECMO / ECLS, compared to patients with ARDS or cardiogenic shock without ECMO / ECLS

Interventions

BIOLOGICALBlood test

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient older than 18 years old * Patient hospitalized in an intensive care unit * Patient whose initial ARDS or Cardiogenic shock began less than 5 days before admission * Patients hospitalized for ARDS or Cardiogenic shock with ECMO / ECLS or - Patients hospitalized for ARDS or Cardiogenic shock without ECMO / ECLS

Exclusion criteria

* Opposition of patient, relative or legal representative for participation in the study * Pregnant woman * Pre-immunodepression * Implementation of immunosuppressive therapy such as chemotherapy, cyclophosphamide, high-dose corticosteroids (\> 0.5mg / kg / day).

Design outcomes

Primary

Measure	Time frame
Prevalence of immunosuppression in patients with ARDS or cardiogenic shock under ECMO / ECLS hospitalized in intensive care unit	Hour 24

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026